Similar to inactivation of SUPT16H, SETD2 loss of function sensitized A549 and H358 (a human KRAS mutant lung cancer cell line) to apoptosis triggered by the FACT complex inhibitor CBL0137 (44) (Figure 7G). Here, SUPT16H is linked to lung carcinoma.